8-K: Immix Biopharma 2026 Annual Meeting Voting Results
Annual Meeting Results
Immix Biopharma stockholders re-elected all director nominees and ratified the appointment of Crowe LLP as independent auditors.
Summary
- The 2026 Annual Meeting of stockholders was held on May 22, 2026.
- Stockholders elected nine directors to the board: Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, Helen C. Adams, Carey Ng, Jane Buchan, Yekaterina Chudnovsky, and Nancy Chang.
- The appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 42,276,496 votes in favor.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it reflects routine corporate governance and the successful completion of standard annual meeting requirements.
Positives
- Strong shareholder support for the board of directors, with all nominees receiving a significant majority of votes cast.
- Overwhelming approval for the ratification of Crowe LLP as the company's independent auditor.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that this filing represents standard annual corporate governance procedures for a Nasdaq-listed biotechnology company, indicating stability in board composition and audit oversight.
Comparison to Industry Standards
- The election of directors and ratification of auditors are standard annual requirements for U.S. public companies.
- The voting turnout and approval margins are consistent with typical results for small-cap biotechnology firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Election | Election of nine directors to serve until the next annual meeting. | 2026-05-22 | Maintains continuity in corporate leadership and oversight. |
Stakeholder Impact
- Shareholders maintain continuity in board representation.
- The company retains its current independent audit firm, ensuring consistency in financial reporting.
Next Steps
- Continue operations under the newly elected board of directors.
- Proceed with Crowe LLP as the independent auditor for the 2026 fiscal year.
Key Dates
| Date | Description |
|---|---|
| 2026-04-06 | Definitive Proxy Statement filed with the SEC. |
| 2026-05-22 | Date of the 2026 Annual Meeting of stockholders. |
| 2026-05-29 | Date of the 8-K filing signature. |
Keywords
Immix Biopharma, IMMX, Annual Meeting, Proxy Voting, Corporate Governance, Board Election
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.